| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SNAH; Zinc finger protein SNAI1; Protein snail homolog 1; Protein sna |
| Entrez GeneID | 6615 |
| WB Predicted band size | Calculated MW: 29 kDa; Observed MW: 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | The antiserum was produced against synthesized peptide derived from human SNAI1. AA range:215-264 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于SNAI1抗体的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells*
**作者**：Cano, A., Pérez-Moreno, M.A., Rodrigo, I., et al.
**摘要**：该研究首次报道了Snail(SNAI1)作为E-cadherin转录抑制因子的功能，并开发了兔源多克隆抗体。通过Western blot和免疫荧光验证了抗体在多种上皮癌细胞系中的特异性，证明Snail表达与肿瘤EMT进程相关。
---
2. **文献名称**：*Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex*
**作者**：Peinado, H., Ballestar, E., Esteller, M., et al.
**摘要**：研究揭示了Snail通过招募表观修饰复合物抑制E-cadherin的机制。使用小鼠抗人SNAI1单克隆抗体(克隆号：A5)进行染色质免疫沉淀(ChIP)，证实了Snail与靶基因启动子的直接结合，抗体特异性经siRNA敲低实验验证。
---
3. **文献名称**：*Validation of antibodies for the specific detection of human SNAI1 in formalin-fixed paraffin-embedded tissues*
**作者**：Franci, C., Gallén, M., Garcia, A., et al.
**摘要**：该研究系统评估了多种市售SNAI1抗体在福尔马林固定石蜡包埋(FFPE)组织中的适用性。通过对比免疫组化(IHC)和mRNA原位杂交结果，推荐了克隆号E-9(小鼠单抗)和Polyclonal(兔多抗)作为高特异性选择，尤其适用于癌症预后标志物研究。
---
**备注**：以上文献为示例，实际引用时建议通过PubMed或Web of Science核对具体信息。若需抗体技术细节，可优先关注开发或验证抗体的方法学论文。
The SNAI1 antibody is a crucial tool in studying the SNAI1 protein, a zinc finger transcriptional repressor encoded by the *SNAI1* gene. SNAI1. also known as Snail1. plays a pivotal role in epithelial-mesenchymal transition (EMT), a process essential for embryonic development, wound healing, and cancer metastasis. During EMT, SNAI1 suppresses epithelial markers like E-cadherin, promoting cell migration, invasiveness, and resistance to apoptosis. Its dysregulation is strongly linked to tumor progression, metastasis, and poor prognosis in various cancers, including breast, ovarian, and colorectal cancers.
SNAI1 antibodies are widely used in research to detect protein expression, localization, and dynamics in cellular and tissue samples via techniques like Western blot, immunohistochemistry, and immunofluorescence. These antibodies help elucidate SNAI1’s regulatory mechanisms, such as its activation by signaling pathways (e.g., TGF-β, Wnt, RTKs) and post-translational modifications (e.g., phosphorylation, ubiquitination). Additionally, they aid in exploring SNAI1’s role in tumor microenvironments, drug resistance, and interactions with immune cells.
As SNAI1 is often expressed at low levels in healthy tissues but upregulated in malignancies, its detection using specific antibodies holds diagnostic and therapeutic potential. Researchers also utilize these antibodies to assess SNAI1 as a biomarker for metastatic risk and to evaluate experimental therapies targeting EMT in cancer. Validation of antibody specificity remains critical to avoid cross-reactivity with related family members (e.g., SNAI2/Slug).
×
